This week in therapeutics




Licensing status

Publication and contact information


Brain cancer

Cytosolic branched chain amino-acid transaminase 1 (BCAT1); isocitrate dehydrogenase 1 (IDH1)

Patient tissue and mouse studies suggest inhibiting BCAT1 could be useful for treating gliomas with wild-type IDH1. In patient samples, BCAT1 was overexpressed in wild-type IDH1 gliomas and downregulated in mutant IDH1 gliomas. In a mouse xenograft model for wild-type IDH1 human glioma, small hairpin RNA against BCAT1 decreased tumor growth compared with nontargeting shRNA. Next steps could include identifying and evaluating small molecule BCAT1 inhibitors in gliomas with wild-type IDH1.

SciBX 6(29); doi:10.1038/scibx.2013.748
Published online Aug. 1, 2013

Patent and licensing status unavailable

Tönjes, M. et al. Nat. Med.; published online June 23, 2013;
Contact: Bernhard Radlwimmer, German Cancer Research Center, Heidelberg, Germany